Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
Clinical trial NCT04623216 · TERMINATED
Trial details
- NCT number
- NCT04623216
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-14
- Primary completion
- 2024-08-22
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.